Poor
Needs Major Revision
Patient Risk:
Low
Summary
Most extracted claims are absent from the provided FDA prescribing information; only dosing-initiation statements (2.5 mg starting dose and initiation purpose) are partially supported.
Category Scores
Accurate Statements
In Japan (as elsewhere), tirzepatide products are typically used starting at 2.5 mg as an initial dose before titrating upward.
Label supports a recommended starting dosage of 2.5 mg once weekly with dosage escalation (2.1 Recommended Dosage).
In the initial weeks, the billed drug strength is still 2.5 mg.
Label states 2.5 mg is for treatment initiation and is followed by increase after 4 weeks (2.1 Recommended Dosage).
Unsupported Statements
Mounjaro out-of-pocket price in Japan depends on the exact product strength.
Absent from the provided label sections.
Mounjaro out-of-pocket price in Japan depends on whether it is dispensed through the national health insurance system.
Absent from the provided label sections.
Mounjaro out-of-pocket price in Japan depends on the pharmacy that fills the prescription.
Absent from the provided label sections.
Japan pricing for Mounjaro changes over time (for example, at reimbursement/market updates).
Absent from the provided label sections.
The only reliable way to confirm today’s price is to check the latest listing tied to the specific package size and dosage form.
Absent from the provided label sections.
Patients’ out-of-pocket costs for a medicine can differ due to insurance coverage level and copay category.
Absent from the provided label sections.
Patients’ out-of-pocket costs for a medicine can differ due to deductions/ceilings under Japan’s high-cost medical system.
Absent from the provided label sections.
Patients’ out-of-pocket costs for a medicine can differ due to pharmacy dispensing charges.
Absent from the provided label sections.
Mounjaro is protected by patent/exclusivity in many markets.
Absent from the provided label sections.
Patent/exclusivity can affect market availability of Mounjaro.
Absent from the provided label sections.
Patent/exclusivity can affect whether competing versions enter the market.
Absent from the provided label sections.
Contradictions
Important Omissions
No label-relevant content was provided regarding FDA-specific contraindications, boxed warnings, warnings/precautions, drug interactions, monitoring, or administration beyond the limited dosing-initiation statements.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Unsupported claims primarily concern non-label topics (Japan-specific out-of-pocket pricing and patent/exclusivity). The only label-supported content relates to the 2.5 mg starting dose and escalation timing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Major Revision
Primary Issue
Most statements are absent from the provided FDA label content (pricing mechanisms in Japan and patent/exclusivity claims).
Suggested Improvement
Remove or replace Japan pricing/patent/exclusivity claims with information supported by the FDA label; retain only label-supported dosing initiation and escalation statements from section 2.1.